NEW YORK--(BUSINESS WIRE)--Third paragraph, first sentence of release should read: (1) Defendants recklessly issued guidance for 2025 that they knew or should have known was not going to be achieved ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Agilon Health, Inc. (NYSE: AGL) securities between February 26, 2025, and August 4, 2025, alleging that the company misled investors regarding its business prospects [1] Allegations - The complaint asserts that Agilon Health, Inc. failed to disclose that it issued guidance for 2025 that was unrealistic, given the material industry challenges they were aware of, and that they materially overstated the financial benefits from strategic actions taken to mitigate risks [2] Company Developments - On August 4, 2025, Agilon announced the resignation of Steven Sell as President, CEO, and Director, stating that his departure was a termination without 'cause' according to his employment agreement. The same day, the company released disappointing financial results, leading to a stock price drop of over 50%, closing at $0.8801 on August 5, 2025 [3] Class Action Participation - Shareholders may be eligible to participate in the class action against Agilon Health, Inc. Those interested in serving as lead plaintiffs should contact Robbins LLP. Participation is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of agilon health, inc. (NYSE: AGL) between February 26, 2025 and August 4, 2025, both dates inclusive (the "Class Period†). The lawsuit seeks to recover damages for agilon investors under the federal securities laws. To join the agilon class action, go to https://rosenlegal.com/submit-form/?case_id=46039 or call Phillip Kim, Esq. t. ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Agilon Health, Inc. (NYSE: AGL) towards shareholders [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Agilon may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Agilon Health [2]. Group 2: Company Performance and Market Reaction - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering substantial amounts for investors [4].

Summary of Agilon Health FY Conference Call (December 02, 2025) Company Overview - **Company**: Agilon Health (NYSE: AGL) - **Industry**: Healthcare Services, specifically focused on Medicare Advantage and value-based care models Key Points and Arguments Business Transition and Contracting Cycle - The company is undergoing a long-cycle business transition, with 50% of contracts open for the year, many being multi-year contracts [4][3] - Improvements made in the current year will not impact the profit and loss statement until the following year, indicating a longer economic cycle in the industry [4][3] Contracting Strategy - Agilon Health has focused on achieving appropriate economics for the value delivered to payer partners, with a disciplined approach to contracting [5][5] - In 2024, 60% of contracts included Part D risk, which is expected to decrease to 30% in 2025, with further improvements anticipated in 2026 [5][5] - The company is removing elements from contracts that introduce variability, such as Part D and supplemental benefits [6][6] Quality and Risk Adjustment - The company has a $25 million opportunity for quality performance in 2025, which is expected to double in 2026 [14][14] - Agilon is focusing on STAR scores, which have a long delay but are crucial for quality performance and financial incentives [14][14] Regulatory Landscape and Risk Management - The company is actively narrowing the risks it takes on, particularly concerning items outside its control, such as Part D and supplemental benefits [13][13] - Agilon has implemented a data pipeline to improve visibility into member-level premiums and costs, aiding in managing regulatory changes [16][16] Financial Outlook - The company expects to end 2025 with $300 million in cash and $100 million by the end of 2026, indicating good visibility into cash flow based on 2025 performance [66][66] - The benchmark rate for Medicare Advantage is expected to increase by approximately 9%, which is seen as a tailwind for the company [33][33] Market Dynamics and Growth Strategy - Agilon has paused growth initiatives for 2025 and 2026 to focus on improving profitability, despite strong demand from primary care partners [30][30] - The company has exited markets that do not present a near-term path to profitability, affecting approximately 29,000 members [30][30] Physician Partnerships - The company reports a high retention rate among physician partners, indicating strong relationships and engagement in driving improved economics [59][59] - There is ongoing demand for value-based care partnerships, despite macroeconomic challenges [62][62] Future Expectations - The company is optimistic about its positioning for 2026 and beyond, with plans to return to growth once a solid foundation is established [62][62] - Agilon is focused on executing strategies in 2025 that are expected to drive superior value in 2026 [77][77] Additional Important Insights - The regulatory environment is dynamic, and the company must remain nimble to adapt to changes, such as those in the ACO REACH program [20][20] - The discussions with payer partners have been constructive, with a focus on joint value creation and reducing volatility in contracts [36][36] - The company is working on improving cash and liquidity management, which is crucial for its operational model [37][37] This summary encapsulates the key points discussed during the Agilon Health FY Conference Call, highlighting the company's strategic focus, market dynamics, and financial outlook.

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Shareholders who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without incurring out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - Investors are encouraged to join the prospective class action by contacting the Rosen Law Firm for more information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Agilon Health, Inc. (NYSE: AGL), urging shareholders to take action promptly due to possible time limitations on enforcing their rights [1]. Group 1: Shareholder Rights and Actions - Long-term shareholders of Agilon may seek corporate governance reforms, recovery of funds, court-approved financial incentives, or other benefits [2]. - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced transparency, accountability, and overall shareholder value [3]. Group 2: Legal Representation and Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].